sub:assertion {
  d:DB06168 v:identifier "DB06168" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB06168" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB06168> ;
    dv:drugbank-id "DB06168" ;
    dv:x-atc <http://bio2rdf.org/atc:L04AC08> ;
    dv:x-cas <http://bio2rdf.org/cas:914613-48-2> ;
    dv:x-kegg <http://bio2rdf.org/kegg:D09315> ;
    dv:x-ndc <http://bio2rdf.org/ndc:0078-0582-61> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Canakinumab> ;
    dct:description "Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients."@en ;
    dct:identifier "drugbank:DB06168" ;
    dct:title "Canakinumab"@en ;
    a dv:Drug ;
    rdfs:label "Canakinumab [drugbank:DB06168]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB06168> , <http://www.drugs.com/mtm/canakinumab.html> , <http://www.rxlist.com/ilaris-drug.htm> .
}